Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis

Joanna R. Kingery, Kevin M. Sowinski, Michael A. Kraus, James E. Klaunig, Bruce A. Mueller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

Original languageEnglish (US)
Pages (from-to)653-656
Number of pages4
JournalPharmacotherapy
Volume20
Issue number6 I
DOIs
StatePublished - Jan 1 2000

Fingerprint

Vancomycin
Chronic Kidney Failure
Renal Dialysis
Fluorescence Polarization Immunoassay
Enzyme Multiplied Immunoassay Technique
Artificial Kidneys
Permeability
Outpatients
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Kingery, J. R., Sowinski, K. M., Kraus, M. A., Klaunig, J. E., & Mueller, B. A. (2000). Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. Pharmacotherapy, 20(6 I), 653-656. https://doi.org/10.1592/phco.20.7.653.35177

Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. / Kingery, Joanna R.; Sowinski, Kevin M.; Kraus, Michael A.; Klaunig, James E.; Mueller, Bruce A.

In: Pharmacotherapy, Vol. 20, No. 6 I, 01.01.2000, p. 653-656.

Research output: Contribution to journalArticle

Kingery, JR, Sowinski, KM, Kraus, MA, Klaunig, JE & Mueller, BA 2000, 'Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis', Pharmacotherapy, vol. 20, no. 6 I, pp. 653-656. https://doi.org/10.1592/phco.20.7.653.35177
Kingery, Joanna R. ; Sowinski, Kevin M. ; Kraus, Michael A. ; Klaunig, James E. ; Mueller, Bruce A. / Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. In: Pharmacotherapy. 2000 ; Vol. 20, No. 6 I. pp. 653-656.
@article{e8c9d54a79e74d2aa17e8623f7909ec1,
title = "Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis",
abstract = "Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.",
author = "Kingery, {Joanna R.} and Sowinski, {Kevin M.} and Kraus, {Michael A.} and Klaunig, {James E.} and Mueller, {Bruce A.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1592/phco.20.7.653.35177",
language = "English (US)",
volume = "20",
pages = "653--656",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6 I",

}

TY - JOUR

T1 - Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis

AU - Kingery, Joanna R.

AU - Sowinski, Kevin M.

AU - Kraus, Michael A.

AU - Klaunig, James E.

AU - Mueller, Bruce A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

AB - Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

UR - http://www.scopus.com/inward/record.url?scp=0034040011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034040011&partnerID=8YFLogxK

U2 - 10.1592/phco.20.7.653.35177

DO - 10.1592/phco.20.7.653.35177

M3 - Article

C2 - 10853620

AN - SCOPUS:0034040011

VL - 20

SP - 653

EP - 656

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6 I

ER -